首页> 外文期刊>The economist >A pair of aces
【24h】

A pair of aces

机译:一对aces

获取原文
获取原文并翻译 | 示例
           

摘要

GOOD NEWS from covid-19 wards is hard to come by. A relentless surge in infections is overwhelming hospitals around the world. But the results from a clinical trial of two drugs, announced on January 7th, have improved the prognosis for both patients and hospitals. The drugs in question, tocilizumab and sarilumab, are currently used to reduce inflammation in patients with arthritis. Hyper-inflammation, whereby the immune system goes into overdrive and destroys a patient's organs, is how covid-19 tends to kill. The search for suitable anti-inflammatory drugs to treat it has already turned up one, dexamethasone. This is a cheap steroid that dampens the immune system across the board. Tocilizumab and sarilumab, by contrast, are more focused. They are both antibodies that block the effect of interleukin-6, a protein that stokes the immune response and has been prominent in patients with covid-19.
机译:来自Covid-19病房的好消息很难得到。 感染的无情飙升是世界各地的医院。 但是,两种药物临床试验的结果,1月7日宣布,患者和医院的预后提高了预后。 有问题的药物,托尔替代和撒拉米布目前用于减少关节炎患者的炎症。 超炎症,从而免疫系统进入过驱动并摧毁患者的器官,是Covid-19如何遭受的侵害。 寻找合适的抗炎药物治疗它已经出现了一种,地塞米松。 这是一种廉价的类固醇,可以在董事会上抑制免疫系统。 相比之下,丁玺和撒拉氏菌布更集中。 它们都是阻断白细胞介素-6的抗体的抗体,这是一种刺激免疫反应的蛋白质,并且在Covid-19患者中突出的蛋白质。

著录项

  • 来源
    《The economist》 |2021年第9228期|共1页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号